Edwards Lifesciences reported positive two-year clinical data for its EVOQUE transcatheter tricuspid valve replacement (TTVR) system, demonstrating sustained patient benefits.

Results from the TRISCEND II Phase III trial showed near elimination of tricuspid regurgitation, improved quality of life, and significantly lower mortality when accounting for patient crossover, with no additional device-related safety risks.

The data, presented at the American College of Cardiology Annual Scientific Session, reinforce the system’s effectiveness in treating patients with limited options for this condition.

The findings support the growing clinical evidence for the EVOQUE system, which is already approved in the U.S. and Europe, highlighting its potential to transform treatment for structural heart disease.
Business Wire